{"id":219254,"date":"2023-09-04T19:28:12","date_gmt":"2023-09-04T19:28:12","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=219254"},"modified":"2023-09-04T19:28:12","modified_gmt":"2023-09-04T19:28:12","slug":"epidemia-de-obezitate-fenomenul-ozempic-are-puterea-de-a-perturba-industrii-intregi-americanii-isi-iau-al-doilea-job-si-credite-pentru-a-cumpara-medicamentul-miracol","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=219254","title":{"rendered":"Epidemia de obezitate: fenomenul Ozempic are puterea de a perturba industrii \u00eentregi. Americanii \u00ee\u015fi iau al doilea job \u015fi credite pentru a cump\u0103ra medicamentul \u201emiracol\u201c"},"content":{"rendered":"<p>\n<span style=\"font-size: 12px;\">Europa se confrunt\u0103 cu o epide\u00admie de obezitate, iar acest lucru \u00eence\u00adpe s\u0103 se vad\u0103 \u00een modul \u00een care \u00ee\u015fi va\u00adlorizeaz\u0103 companiile, potrivit Quartz. Novo Nordisk, compania farma da\u00adne\u00adz\u0103 care produce popularele medi\u00adca\u00admente de sc\u0103dere a greut\u0103\u0163ii Ozempic \u015fi Wegovy, a dep\u0103\u015fit la \u00eenceputul lunii septembrie pentru scurt timp capita\u00adlizarea de pia\u0163\u0103 a LVHM.<\/span><\/p>\n<p>\n\u00cens\u0103 cre\u015fterea Novo este pe cale s\u0103 continue, dup\u0103 ce s-a triplat \u00een ultimii trei ani, \u00een timp ce cea a LVHM s-a dublat.<\/p>\n<p>\nTendin\u0163a ar putea semnala c\u0103 eu\u00adropenilor le pas\u0103 de sc\u0103derea greut\u0103\u00ad\u0163ii la fel de mult ca de posesia de bunuri de lux. Aproximativ 59% din adul\u0163ii \u015fi aproape 1 din 3 copii din Europa este supraponderal sau tr\u0103ie\u015fte cu obezitatea, relev\u0103 un ra\u00adport recent al Organiza\u0163iei Mondiale a S\u0103n\u0103t\u0103\u0163ii. Prevalen\u0163a obezit\u0103\u0163ii din Europa este mai ridicat\u0103 dec\u00e2t cea din orice alt\u0103 regiune a OMS cu excep\u0163ia Americilor.<\/p>\n<p>\nNovo a anun\u0163at c\u0103 medicamentul s\u0103u Wegovy ar putea diminua riscul de atac de cord sau infarct cu 20% la cei supraponderali sau obezi cu probleme de inim\u0103. Ozempic scade concentra\u0163ia de zah\u0103r din s\u00e2nge \u015fi este la mare c\u0103utare ca medicament extrem de eficient \u00eempotriva diabetu\u00adlui \u015fi pentru sc\u0103derea greut\u0103\u0163ii.<\/p>\n<p>\nPia\u0163a acestui tip de medicamente este a\u015fteptat\u0103 s\u0103 \u00eenregistreze v\u00e2nz\u0103ri anuale de 100 miliarde de dolari \u00een urm\u0103torii 10 ani.<\/p>\n<p>\nRetailerii, produc\u0103torii de ali\u00admen\u00adte prezentate ca av\u00e2nd efect de sc\u0103dere a greut\u0103\u0163ii \u015fi alte tipuri de com\u00adpanii ar putea resim\u0163i efectele popularit\u0103\u0163ii \u00een cre\u015ftere a medica\u00admentelor ca Ozempic, scrie The New York Times.<\/p>\n<p>\nOportunit\u0103\u0163ile, at\u00e2t de a face pro\u00adfit, c\u00e2t \u015fi de a pierde averi, ar pu\u00adtea fi vaste nu numai pentru compa\u00adniile din spatele acestor medica\u00admen\u00adte, dar \u015fi pentru unele din industrii complet diferite.<\/p>\n<p>\n\u00cen America, pentru c\u0103 aceste me\u00addi\u00adcamente sunt scumpe \u015fi nu sunt aco\u00adperite de asigur\u0103ri, oamenii \u00ee\u015fi iau al doilea job sau apeleaz\u0103 la cardu\u00adri\u00adle de credit, scrie Wall Street Journal.<\/p>\n<p>\nUnii consumatori pl\u0103tesc 10.000 de dolari pe an sau peste pentru a ob\u0163ine medicamentele populare ale Eli Lilly \u015fi Novo Nordisk. Pacien\u0163ii \u00ee\u015fi iau al doilea job, apeleaz\u0103 la credite sau \u00ee\u015fi restr\u00e2ng cheltuielile pe c\u0103l\u0103torii pentru a-\u015fi permite astfel de medi\u00adcamente.<\/p>\n<p>\nCompaniile farma chineze dezvolt\u0103 versiuni locale ale acestor medicamente \u201eminune\u201c, conform Financial Times. Acestea sper\u0103 s\u0103 concureze cu medicamentele Novo Nordisk \u00een China, care are cea mai mare popula\u0163ie supraponderal\u0103 \u015fi diabetic\u0103 din lume. Dac\u0103 vor avea succes, acestea ar putea oferi de asemenea o alternativ\u0103 mai ieftin\u0103 \u00een vest.<\/p>\n<p>\nTotu\u015fi, avertizeaz\u0103 David Ludwig, specialist \u00een obezitate la Harvard Medical School, \u201eaceste medicamente sunt revolu\u0163ionare, dar cu un asterisc\u201c, \u00een condi\u0163iile existen\u0163ei unei liste lungi de efecte secundare.<\/p>\n<p>\nNovo este de acord, scrie New York Times. \u00cen iunie, compania a lansat o unitate de preven\u0163ie a obezit\u0103\u0163ii \u00een apropiere de Copenhaga, pentru a cerceta cum poate fi oprit\u0103 boala \u00eenainte ca oamenii s\u0103 fie nevoi\u0163i s\u0103 ia medicamente pentru a sc\u0103dea \u00een greutate.<\/p>\n<p>\n&nbsp;<\/p>\n<p>\n&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Europa se confrunt\u0103 cu o epide\u00admie de obezitate, iar acest lucru \u00eence\u00adpe s\u0103 se vad\u0103 \u00een modul \u00een care \u00ee\u015fi va\u00adlorizeaz\u0103 companiile, potrivit Quartz. Novo Nordisk, compania farma da\u00adne\u00adz\u0103 care produce popularele medi\u00adca\u00admente de sc\u0103dere a greut\u0103\u0163ii Ozempic \u015fi Wegovy, a dep\u0103\u015fit la \u00eenceputul lunii septembrie pentru scurt timp capita\u00adlizarea de pia\u0163\u0103 a LVHM. \u00cens\u0103 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[13794,485,18962,323,16559],"class_list":["post-219254","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-americani","tag-credite","tag-epidemie","tag-medicamente","tag-obezitate"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/219254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=219254"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/219254\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=219254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=219254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=219254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}